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Problem: Although pharmacotherapy is an effective treatment for many psychiatric disorders 
in children and adolescents, medication adherence rates among children are low. This study 
clarifies factors affecting children’s medication adherence and the role of parental 
involvement. 
Method: Patients aged 7–17 years with a history of psychotropic medication treatment and 
their mothers were included in this study. Each mother and child completed self-administered 
questionnaires. Thirty mother–child pairs who fully completed the questionnaires were 
included in the analysis.  
Results: Medication adherence was greater in children and mothers when mothers felt that 
“children’s symptoms improved with treatment and medication.” Medication adherence in 
children and mothers significantly correlated with the child’s reported trust in their parent.  
Conclusions: The results suggest the need for psychosocial support that considers the 
influence of mothers on medication adherence in children treated in child psychiatry 
departments. 
Keywords: Medication Adherence, Children and Adolescents, Outpatient 
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 In general, child and adolescent psychiatric patients are treated with a combination of 
psychosocial interventions and pharmacotherapy. For many diseases or severities of illness, 
guidelines recommend pharmacotherapy as the first line of treatment because of its high 
therapeutic efficacy. The use of psychotropic medications among children with psychiatric 
problems can improve not only psychological symptoms, but also quality of life, academic 
performance, and relationships with friends, family, and others (Hamrin, McCarthy, & Tyson, 
2010). Despite these benefits, children generally exhibit lower rates of medication adherence. 
Without adequate treatment, these patients are at risk for more severe psychiatric symptoms, 
declining academic performance, interpersonal problems, suicide, and family stress (Hamrin 
2010). Children’s medication adherence rates vary between 13.2% and 89.8%, and the 
majority of studies demonstrating high adherence rates adopt a child or caregiver 
self-assessment (Adler & Nierenberg, 2010; Hamrin et al., 2010). However, adherence rates 
assessed through self-report are likely to be higher than actual adherence rates (Pappadopulos 
et al., 2009; Yang et al., 2012).  
In recent years, many studies have acknowledged the willingness of children to take 
medications. For instance, Floersch et al. (2009) conducted interviews with adolescents about 
their subjective experiences with psychotropic medication therapy and found that although 
youth believed in the need for and effectiveness of psychotropic medication, they had many 
questions about how these medications work and substantial concerns about side effects. 
Floersch et al. (2009) suggested that these results occurred because of a large gap in the 
experience and knowledge of youth regarding the effects and side effects of medication. 
Additionally, Kranke et al. (2011) conducted interviews with adolescents about their 
subjective experiences with psychotropic medication therapy, and found an association 
between taking medications and self-stigma. Specifically, many adolescents had experienced 
stigma and shame related to their condition and therefore preferred not to disclosing their use 
2 
of psychotropic medication. In another study, Brinkman et al. (2012) interviewed adolescents 
aged 13 to 18 years with attention deficit hyperactivity disorder (ADHD). Here, it was 
demonstrated that when trying to understand their symptoms and the necessity for medication, 
adolescents frequently compared their mental condition with and without medication. 
Townsend et al. (2009) demonstrated the effectiveness of evaluating adolescent patients’ 
adherence to psychotropic medications with the Drug Attitude Inventory-30 (DAI-30), which 
evaluates patients’ subjective attitudes about medication. However, evaluating patient 
adherence to antidepressants or stimulants using the DAI-30 is insufficient because this 
measure was specifically designed to assess the attitudes of adults with schizophrenia who 
take anti-psychotic medications. Altogether, children and adolescents seem to recognize the 
importance psychotropic medications, and medication adherence in child and adolescent 
psychiatry should be assessed in terms of willingness. The various factors affecting this 
willingness to take psychotropic medications should be more closely examined.  
The factors influencing children’s medication adherence include the following: (1) 
presence of comorbidity (e.g., ADHD with depression, ADHD with anxiety disorder, and 
schizophrenia with depression increase adherence; ADHD with oppositional disorder or 
borderline personality disorder decrease adherence); (2) particular prescriptions and dosages; 
(3) adverse reactions to medications; (4) social stigma about psychiatric treatment or 
psychotropic medication; and (5) children’s understanding of the reasons for taking 
medication (Charach & Gajaria, 2008; Hamrin et al., 2010; Lloyd et al., 1998). Further 
interacting with these factors to affect adherence are family issues, each child’s individual 
issues, and the nature of specific treatments. For instance, in one study, Charach, Volpe, 
Boydell, and Gearing (2008) identified predictors of adherence to psychostimulants in 
children with ADHD and found four significant factors: the children, their parents/families, 
the health care professionals, and the prescribed medications. 
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Previous studies have revealed that parental awareness of treatment risks and benefits 
is closely related to children’s adherence (Hoza, Johnston, Pillow, & Ascough, 2006). 
Furthermore, both children’s knowledge about the reasons for taking medication and their 
parents’ views on medications affect the continued use of medications (Thorell & Dahlström, 
2009). Since parental consent is necessary for children to receive medical treatment, parents 
select their children’s treatments. It is natural, therefore, that parental awareness of their 
children’s symptoms and treatments can significantly affect the course of treatment 
(Brinkman et al., 2012). While children are young, parents are actively involved in their 
child's medication management. However, as the child grows older, parents gradually transfer 
responsibility for medication management to their child. During adolescence, many children 
begin to manage their own medication and are more in control of continuing 
psychopharmacology. Young adolescents, however, may have different views about taking 
the medications than their parents. For example, adolescents differ from their parents in their 
beliefs about ADHD and their attitude about medication use (Charch, Yeung, Volpe, Goodale, 
& dosReis, 2014), and adolescents are less willing to treat their ADHD with medications than 
their parents (Bussing, Koro-Ljungberg, Noguchi, Mason, Mayerson, & Garvan, 2012). 
In order for children to continue receiving appropriate treatments, we must improve 
adherence by addressing the factors affecting child and adolescent willingness to take 
psychotropic medications. In particular, it is important to assess the effects of parental 
adherence and attitudes and how these relate to children’s adherence. Furthermore, it is 
necessary to clarify any age-related differences in the influence of parents. In this study, we 
examined the factors affecting medication adherence among both mothers and their children 
in child and adolescent psychiatry departments as well as the associations between maternal 




Outpatients and their mothers visiting a child and adolescent psychiatry or pediatrics 
department in Nagasaki Prefecture were included in this study. Five hospitals collaborated on 
this research. All patients were taking psychotropic medications upon diagnosis according to 
the International Statistical Classification of Diseases and Related Health Problems, 10th 
Revision (ICD-10). Since there is no advanced practice nursing system in Japan, all patients 
had been prescribed the psychotropic medication by physicians. Exclusion criteria were being 
younger than 7 or older than 18 years of age, illiteracy, severe autism, and having an 
intelligence quotient (IQ) of less than 70. Thirty-seven mother–child pairs were referred to 
study researchers by their attending doctors, and 33 of these pairs consented to participate in 
the study.  
Procedure 
A survey of mothers and their children was conducted concurrently using a mailed 
questionnaire. It was necessary to mail the questionnaire to respondents because there were 
instances where only the child or mother visited the hospital. This survey was conducted over 
a period of two months from August to September 2009. The aims and ethical considerations 
of this study were explained prior to participation, and written consent to participate in the 
survey was obtained from both mother and child. Ethical approval for the study was obtained 
from the Ethics Committee of the University where the researchers were employed. 
Materials 
Demographic and clinical characteristics. Along with several questionnaires, the 
survey consisted of questions about participants’ demographics and clinical characteristics. 
Children were asked six items including age, gender, name of attending physician, name of 
medication administered, reasons for medication, and if they had received an explanation 
about the medication. Mothers were asked seven items including age, family composition, 
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history of psychiatric treatment, treatment history with psychotropic medications, child’s 
history of clinic visits, the relationship between changes in their children and the effects of 
medications following clinic visits, and if they were close to one or more individuals who 
were taking psychotropic medications. The researchers also interviewed patients’ attending 
physicians for further information on children’s psychiatric diagnoses and medications. 
Child Adherence Questionnaire. The Child Adherence Questionnaire (CAQ) is a 
scale created by Nagae, Honda, and Hanada (2011) based on the Drug Attitude Inventory-10 
(DAI-10) (Hogan, Awad, & Eastwood, 1983) to measure adherence in children receiving 
pharmacotherapy with psychotropic medications. The scale consists of two factors (“attitude 
toward medication” and “awareness of medication influences”) with a total of 25 items to 
which individuals can respond either “YES” or “NO.” Positive and negative answers are 
given a score of +1 and -1, respectively. Total scores on the scale are then calculated, with 
higher scores indicating better adherence. Total scores range from -25 to +25 points. Scores 
for “attitude toward medication” and “awareness of medication effects” can range from -10 to 
+10 points and -15 to +15 points, respectively. Previous research has demonstrated 
Cronbach’s alpha coefficients of .76 for the CAQ’s total score, .59 for the “attitude toward 
medication” subscale, and .69 for the “awareness of medication influences” subscale (Nagae 
et al., 2011). 
Mother’s Adherence Questionnaire. Nagae, Honda, and Hanada (2010) created the 
Mother’s Adherence Questionnaire (MAQ) to measure adherence in parents whose children 
are treated with psychiatric pharmacotherapy. The MAQ consists of 22 items: 10 derived 
from the DAI-10 (Hogan et al., 1983) about their children’s medication, and 12 related to 
factors affecting the mother’s adherence. Respondents are required to answer questionnaire 
items with either “YES” or “NO.” Positive and negative answers are given a score of +1 and 
-1, respectively. The total score is then calculated, with a higher score indicating better 
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adherence. Scores range from -22 to +22, and the instrument’s Cronbach’s alpha coefficient 
is .72 (Nagae et al., 2010). 
Questionnaire for Parent–Child Mutual Trust. This Japanese scale was created by 
Sakai, Sugawara, Maeshiro, Sugawara, and Kitamura (2002) to measure and bi-directionally 
evaluate parent–child interpersonal trust based on respondents’ expectations of and trust in a 
parent or child. This measure consists of one questionnaire assessing a parent’s trust in their 
child and another assessing a child’s trust in his/her parent. There are paternal and maternal 
versions of each questionnaire. As this study sought to investigate mother–child relations, the 
maternal versions were adopted. Each questionnaire is composed of eight items rated on a 
scale of 1 to 4. For children, the scale options were: 1 = Disagree, 2 = Slightly disagree, 3 = 
Slightly agree, and 4 = Agree. For mothers, the response options were: 1 = Very unlikely, 2 = 
Slightly unlikely, 3 = Slightly likely, and 4 = Very likely. A higher score indicated greater trust. 
The range of possible scores is 8 to 32. In previous research, Cronbach’s alpha coefficients 
of .89 for the children’s maternal trust questionnaire and .85 for the maternal trust in their 
children questionnaire were obtained (Sakai et al., 2002). 
Data Analysis 
Of the 33 mother–child pairs who consented to participate, 30 completed all 
questionnaires with no omissions and were included in data analyses. After a simple 
tabulation was conducted on participants’ demographics, the medians and quartiles of 
participants’ CAQ and MAQ scores were calculated in relation to their demographic 
characteristics. Then Mann-Whitney U and Kruskal-Wallis tests were performed. 
Additionally, Spearman’s rank correlation coefficients were calculated for the MAQ, CAQ, 
and trust scales. Statistical analyses were conducted using PASW Statistics 18.0. All tests 




Participants’ ages (19 boys, 11 girls) ranged from 7 to 17 years (M = 12.9 years, SD = 
2.7). The most prevalent ICD-10 F9 diagnosis code group was “Behavioral and emotional 
disorders with onset usually occurring in childhood and adolescence” (9 cases). 
Antidepressants were the most commonly prescribed medication (17 cases). Three patients 
reported that they did not know about their prescriptions (i.e., the name and reason for taking 
the prescribed medication), and five responded that they had not received any explanation 
about their medications from healthcare professionals. Patients’ mothers were approximately 
40 years of age. Seven of mothers had a personal history of visiting psychiatric clinics and 
nine had a treatment history with psychotropic medications. Moreover, eight mothers 
answered that they had family member(s) other than the child enrolled in the study taking 
psychotropic medications. Of all the mothers surveyed, 25 acknowledged that their children’s 
symptoms had improved after psychiatric clinic visits and 23 recognized that their children’s 
improvement was due to the effects of the medication(s) they had been prescribed.  
Relationships between CAQ or MAQ Scores and Participant Characteristics 
The medians and quartiles of participants’ CAQ and MAQ scores were calculated 
according to demographic and clinical characteristics, and Mann-Whitney U and 
Kruskal-Wallis tests test were conducted (Table 1). Children of mothers who answered 
“YES” to the question “Did you notice an improvement in any of your child’s symptoms after 
visiting the clinic?” scored higher on the CAQ than did children of mothers who answered 
“NO” (p = .065). Further, children of mothers who answered “YES” in response to the 
question “Do you think your child’s improvement is due to his/her taking the medication(s)?” 
scored higher on the CAQ than did children whose mothers answered “NO” (p = .086). 
Mothers scored higher on the MAQ when they answered “YES” to the items: “Did you notice 
an improvement in any of your child’s symptoms after visiting the clinic?” (p =.042), 
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“mother’s treatment history with psychotropic medications” (p = .061), “Do you have any 
family member(s) taking psychotropic medications other than the relevant child?” (p = .056), 
and “Did you think there was an improvement in any of your child’s symptoms after he/she 
took the medications?” (p = .061). Common factors contributing to greater CAQ and MAQ 
scores were “mothers’ recognition of improvements in their children’s symptoms after 
visiting the psychiatry department” and “mothers’ acknowledgement of their children’s 
improvement as the result of the effects of prescribed medication(s).”  
Correlations among Scales 
Spearman’s rank correlation coefficients among the MAQ, CAQ, and mother–child 
trust scale are shown in Table 2. For participants under fourteen years of age, a statistically 
significant correlation was found only between the attitude factor of the CAQ and MAQ 
scores (r = .562, p = .037). For participants fourteen years of age and over, a statistically 
significant correlation was found between CAQ and MAQ scores (r = .724, p = .002). 
Moreover, both the “attitude toward medication” and “awareness of influences of 
medication” factors of the CAQ correlated with MAQ (respectively: r = .535, p = .033; r 
= .612, p = .012). A statistically significant correlation was found between Children’s 
mother–child trust scale scores and both MAQ scores (r = .544, p = .029) and CAQ scores (r 
= .619, p = .011). No statistically significant correlations were found between mothers’ 
mother–child trust scale scores and either MAQ or CAQ scores. 
Discussion 
Factors Affecting Children’s Medication Adherence 
We found no statistically significant difference between CAQ scores and participant 
characteristics (Table 1). However, analyses conducted with a 10% significance threshold 
suggested that potential factors influencing children’s adherence were “mothers’ recognition 
of improvements in their children’s symptoms after visiting the psychiatry department” and 
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“mothers’ acknowledgement of their children’s improvement as the result of the effects of 
prescribed medication(s).” The finding that children’s adherence was associated with 
maternal awareness of the pharmacotherapy is consistent with the results of other studies 
(Hoza et al., 2006; Thorell & Dahlström, 2009). However, unlike previous studies, we found 
no association between adherence and participant characteristics such as gender, age, and 
living with parents. It is likely that these factors were not found in the present study because 
of our relatively small sample size. 
Five children reported that they “did not receive any explanation about the medication 
they were prescribed from healthcare professionals,” and three shared that “they did not know 
much about their prescriptions” (i.e., the name and reasons for taking the medication). We 
must be careful when interpreting this. It is likely that these children had received some 
explanation about the medication when prescribed, however, they may not have understood 
the doctor or may have forgotten the explanation. In general, patients’ understanding and 
acceptance of the need for treatment and medication is strongly associated with adherence 
(Sabate, 2003). In our survey, however, we noted no significant associations between these 
previously mentioned factors and medication adherence.  
 One reason for the lack of significant associations may be the result of the substantial 
participant age range. In a literature review of pediatric psychotropic medication adherence, 
Hamrin (2010) reported that parents exert greater influence on the adherence of younger 
children than on adolescents. Furthermore, this review indicated that younger children exhibit 
better psychotropic medication adherence than older children. According to Piaget’s (1970) 
theory of cognitive development, children 7–11 years of age become capable of logical 
thought under concrete circumstances, yet cannot engage in hypothetical or abstract thought. 
Only after age 11 can children think about abstract concepts, use deductive reasoning, and 
engage in logical, methodical problem-solving. Fitting this model, Floersch et al.’s (2009) 
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found that among 12- to 17-year-olds, adolescents taking psychotropic medications wanted to 
know the reasons for taking medication, the medication’s effects and adverse effects, and how 
to manage their medication. Charch et al. (2014) suggested that incorporating input from 
young adolescents when making clinical decisions could potentially improve continuity of 
ADHD treatment. Thus, in response to changes in children’s awareness of medical regimens 
and mental and social growth, healthcare professionals need to provide adolescent patients 
with the necessary knowledge about their prescribed medications. Overall, they must enable 
children to acquire more knowledge about their treatment.  
Factors Affecting Mothers’ Adherence to their Children’s Medication 
To date, no study in child and adolescent psychiatry has evaluated mothers’ adherence 
to the treatment of their children or the factors affecting this adherence. However, parental 
awareness of a child’s pharmacotherapy can have a profound effect on medication adherence 
and attitudes toward treatment (Brinkman et al., 2012; Charach et al., 2008; Hoza et al., 2006; 
Thorell & Dahlström, 2009). The only factor affecting maternal adherence that was clearly 
found in this study was “mothers’ recognition of improvements in their children’s symptoms 
after visiting the psychiatry department” (Table 1). Other possible influential factors were 
“mothers’ history of visiting psychiatric clinics,” “the presence of close person(s) taking 
psychotropic medications,” and “mothers’ acknowledgement of their children’s improvement 
as the result of the effects of prescribed medication(s).”  
Our evaluation of parental adherence and potentially influential factors suggests 
several implications for both research and practice. Parents visit hospitals with the hope that 
their child’s health will improve. Stigma about psychiatric treatment or pharmacotherapy, 
however, could cause parents to become critical of their child’s treatment (Larson & Corrigan, 
2008). Medical adherence is known to be influenced by how patients understand the effects 
of their treatment and form negative beliefs about the treatment (Sabate, 2003). Similarly, in 
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this study, “actual feelings regarding the effects of psychiatric treatment,” such as “mothers’ 
acknowledgement of their children’s improvement as the result of the effects of prescribed 
medication(s),” were suggested to positively contribute to mothers’ adherence. Additionally, 
adherence was higher in mothers who answered “YES” to questions concerning whether they 
had “a history of visiting psychiatric clinics” or “close person(s) taking psychotropic 
medications.” Possible explanations for this result are that mothers with these experiences 
have less resistance toward treatment with psychotropic medications or more knowledge 
about pharmacotherapy. Thus, they may have fewer negative beliefs regarding treatment or 
feel less stigma about their children being treated with psychotropic medications.  
One effective intervention that could enable mothers to positively influence their 
children’s treatment is to provide mothers with sound psychoeducation about their children’s 
psychological symptoms and pharmacotherapy (Ferrin & Taylor, 2011; Lucksted, McFarlane, 
Downing, & Dixon, 2012). If mothers gain enough knowledge about their child’s disorder or 
treatment, they may better understand the importance of their child’s treatment. In addition to 
reducing stigma, interventions that integrate peer support can produce other benefits such as 
promoting the development of the skills needed to work with their children, problem-solving 
abilities, and access to social supports (Lucksted et al., 2012; Shihabuddeen & Gopinath, 
2005). In these ways, mothers’ adherence to children’s medication can be further improved. 
Relationships between Medication Adherence in Mothers and Children 
In general, parents are responsible for supervising their children’s treatment and 
medication use. Thus, many previous studies have implemented parental educational 
interventions. In this study, among adolescents ages fourteen and older, we observed a 
statistically significant correlation between CAQ and MAQ scores. Both CAQ components 
(“attitude toward medication” and “awareness of influences of medication”) correlated with 
MAQ. However, under fourteen years of age, we found a statistically significant correlation 
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only for the attitude factors of CAQ and MAQ. This suggests that children under fourteen and 
their mothers may disagree in their awareness of the influences of medication. This could be 
the result of children under 14 being unable to convey the influences of medication to their 
mothers. Older children may be more able to convey and communicate their attitudes and 
awareness of the effects of medications. We estimate that mothers may begin transferring 
control of medication management to children when the children are around fourteen years 
old. Moreover, because young children’s attitudes toward medication are affected by their 
mother’s adherence, interventions improving mothers’ understanding of the need for 
medication can attenuate stigma and improve child adherence, even when the child is older 
and more in control.  
The present study did not investigate the extent to which mothers involved their 
children in the management of their medication. This should be clarified in future research. 
When children were fourteen and older, children’s adherence and mother’s adherence were 
both correlated with children’s trust in their mothers, but not with mothers’ trust in their 
children. Consequently, this suggests that children’s medication adherence may be improved 
if maternal adherence is improved, for example, by using a targeted educational intervention. 
Furthermore, this effect may be further enhanced if children’s trust in their mothers is 
increased. For instance, Fristad, Goldberg-Arnold, and Gavazzi (2003) improved family 
interactions and perceptions of parental support as well as parental knowledge about 
childhood mood symptoms by providing group psychoeducation to children with mood 
disorders and their families. It would also be necessary to educate children in order to 
establish stronger mother–child relationships. Specifically, mothers could build their 
children’s trust by working alongside them on their treatments.  
Nursing Implications 
In nursing, the focus is on the whole patient as opposed to the doctor’s focus on the 
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disorder and medical procedures. Nurses assess how the life of the patient has been affected 
by disorder and treatment and provide care accordingly. In particular, in the US, advanced 
practice nurses (APN) are major prescribers of psychotropic medications, and APN tend to 
adapt regimens to patient preference and family and environmental situations, rather than 
simply giving a prescription or instruction (Gillis & Mundinger, 1998). The results of this 
study suggest that for children taking psychiatric medications a careful negotiation with both 
the parent and the improvement of the parent‒child relationship are imperative for APNs to 
influence the family and initiate or sustain medication treatment. In Japan, APN are not 
permit to prescribe medications, but a registered nurse could collaborate with other medical 
professionals to achieve this goal. 
Previous studies have recommended a multimodal intervention rather than relying on 
one single intervention (Drake et al., 2015). This study indicated treatment outcomes may be 
improved by developing a comprehensive intervention program that includes providing both 
the parent and the child with knowledge, improving adherence of both parent and child, 
improving the relationship between parent and child, and promoting peer support. In this 
spirit, we have conducted a group-psychoeducation program focused on promoting adherence 
among children and parents in cooperation with other medical professional that will be the 
subject of a future article. 
Limitations  
A major limitation of this study was its relatively small sample size of 30 
mother–child pairs. This research lacked detailed information regarding past treatments and 
adherence (e.g., whether participants had received some psychoeducation about their 
medication, whether children had actually received an explanation about their medication 
when it was prescribed). However, our results suggest several fundamental ways that 
medication adherence could be improved in child and adolescent psychiatry. The 
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accumulation of a more extensive body of research is needed to enable further in-depth 
investigation. 
Conclusion 
The results of this study suggest two possible factors affecting children’s medication 
adherence. Specifically, these included, “mothers’ recognition of improvements in their 
children’s symptoms after visiting the psychiatry department” and “mothers’ 
acknowledgement of their children’s improvement as the result of the effects of prescribed 
medication(s).” Additionally, other possible influential factors were “mother’s history of 
visiting psychiatric clinics,” “the presence of close person(s) taking psychotropic 
medications,” and “mothers’ acknowledgement of their children’s improvement as the result 
of the effects of prescribed medication(s).” A statistically significant correlation was found 
between children’s and mothers’ adherence; in particular, children’s “attitude toward 
medication” was strongly correlated with mothers’ adherence. While children’s adherence 
correlated with levels of trust in their mothers, it did not correlate with their mothers’ trust in 
the children. The results of this study may be useful in designing nursing interventions to 
support children and adolescents receiving psychiatric treatment with psychotropic 
medication. Future studies that include a more detailed examination of the factors affecting 
medication adherence using a larger sample are required, as well as those that assess 
differences between children and adolescents. 
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Table 1.  Associations Between Participant Characteristics and the CAQ/MAQ (n = 30) 







Children's backgrounds          
 
 
Gendera Male 19  11 (7, 15) .158  11 (7, 17) .210 
Female 11  9 (-3, 13)  7 (3, 15) 
Age (in years)b Primary school 10  9 (3.5, 12) 
.712 
 11 (8, 19) 
.503 Junior high school 14  12 (0, 15)  9 (4, 15.5) 
High school 6  9 (6, 10.5)  9 (4.5, 14) 
Family 
compositiona 
Living with grandparents 
Nuclear family 
8  6 (-2.5, 13) 
.256 
 13 (6.5, 19) 
.219 
22  9 (8.5, 15)  9 (5, 15.5) 
Living with parents 
Single-mother household 
18  9 (0, 15) 
.692 
 9 (5, 15.5) 
.285 
12  10 (5.5, 13)  12 (5.5, 18.5) 
Sibling(s) 
Only child 
20  9 (-0.5, 14.5) 
.397 
 9 (5, 17) 
.397 
10  10 (8.5, 13.5)  11 (8.5, 15.5) 
Mothers' backgrounds             
Age (in years)b Younger than 39 
40 to 44 
45 to 49 
50 or older 
11  9 (7, 15) 
.972 
 11 (9, 19) 
.549 
 10  10 (0, 13.5)  10 (-0.5, 17.5) 
7  9 (-3, 15)  9 (5, 15) 
2  9 (9, 9)  8 (5, 11) 
Mother's history of visiting psychiatric 
clinicsa 
Yes 7  7 (5, 15) 
.666 
 13 (11, 19) 
.061+ 
No 23  9 (3, 13)  9 (5, 15) 
Mother's treatment history with psychotropic 
medicationsa 
Yes 9   11 (8, 15) 
.283 
  11 (9, 14) 
.476 
No 21   9 (0, 13)   9 (4, 18) 
Do you have any family member(s) taking 
psychotropic medications other than the 
relevant child?a 
Yes 8   8 (5.5, 14) 
.801 
  12 (11, 18.5) 
.056+ No 
22   9 (2.5, 13.5)   9 (4.5, 15.5) 
Did you notice an improvement in any of your 
child's symptoms after visiting the clinic?a 
Yes 25   9 (8, 14) 
.065+ 
  11 (6, 17) 
.042* 
No 5   -3 (-6, 11)   5 (-5, 10) 
Do you think your child's improvement is due 
to his/her taking the medication(s)?a 
Yes 23   9 (9, 15) 
.086+ 
  11 (7, 17) 
.061+ 
No 7   3 (-3, 13)   5 (-5, 13) 
Basic information on child's treatment          
 Medical history 
 (months)b 
Less than 1 year 3   15 (-3, 21) 
.366 
 13 (5, 19) 
.747  1 to 3 years 10   8 (-1.5, 13)  12 (1, 19) 
Not less than 3 years 17   9 (8, 14)  9 (5, 13) 
Prescription (multiple answers available)          
 Antipsychotic medicationa 
Yes 9   9 (3, 14) 
.476 
  9 (4, 16) 
.594 
No 21   9 (6, 14)   11 (8, 17) 
 Antidepressanta 
Yes 17   9 (-2, 14) 
.320 
  8 (5, 15) 
.281 
No 13   9 (8, 14)   11 (9, 17) 
 Central nervous system stimulanta 
Yes 7   11 (9, 15) 
.226 
  11 (9, 19) 
.386 
No 23   9 (1, 13)   9 (5, 15) 
 Recognized the attending physician's 
namea 
Yes 23   9 (3, 13) 
.701 
  11 (5, 17) 
.774 
 No 7   9 (9, 15)   9 (1, 17) 
 Understanding of medicationb          
  Knowing the name(s) of and understanding the 
reasons for taking medication 
16   10 (7, 13) 
.125 
  9 (5, 14) 
.518 
  Knowing the name(s) of but not understanding the 
reasons for taking medication 
6   9 (9, 19.5)   14 (7.5, 17.5) 
  Not knowing the name(s) of but understanding the 
reasons for taking medication 
5 
  
15 (0, 18)   9 (0, 16) 
  Not knowing the name(s) of or the reasons for 
taking medication 
3   -1 (-9, 5)   19 (-5, 19) 
 Received an explanation about the 
medication from medical staffa 
Yes 25   9 (7, 14) 
.229 
  11 (5, 16) 
.957 
 No 5   -1 (-12, 14)   9 (0, 19) 
Note. +p < .1, *p < .05; CAQ = Child Adherence Questionnaire; MAQ = Mother's Adherence Questionnaire; 
Q1 = 1st quartile; Q3 = 3rd quartile; 
a.The Mann-Whitney U-test was used for 2 groups, b.The Kruskal-Wallis test was used for 3 or more groups. 
Table 2               
Difference due to age in Correlations Among Scales           
  
    CAQ subscale 
  Scale assessing trust between  
mother and child 
  CAQ 
Attitude toward 
medication 
Awareness of influences 
of medication  
  
Child’s trust in 
his/her mother 
 Mother’s trust 
in her child  





















Age≧14 (n=16)       
















Note. *p < .05, **p < .01; Spearman's rank correlation coefficient. 
CAQ = Child Adherence Questionnaire; MAQ = Mother's Adherence Questionnaire. 
 
